Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Gm6.5
Glucomannan – Forschung
Hilft wahrscheinlich
39 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Glucomannan scheint in 12 von 13 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2005–2026 mit einer typischen Studiengröße von 53 Teilnehmenden.
Basierend auf 39 Studien · 9 Meta-Analysen · 25 RCTs · 9,737 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
12geholfen1unklar· 26 weitere ohne bewertete Effektdaten
Nach Outcome
Weight managementSättigung und verminderte Kalorienaufnahme · 4-8 Wochen
Hilft wahrscheinlich37 Studien
Glucose & metabolicVerlangsamt die Glukoseaufnahme und verbessert das Lipidprofil · 4-12 Wochen
Hilft wahrscheinlich36 Studien
Cholesterol & lipids
Hilft wahrscheinlich34 Studien
Digestive healthPräbiotische Ballaststoffe fördern eine gesunde Darmfunktion und das Mikrobiom · 1-2 Wochen
Hilft wahrscheinlich34 Studien
Heart & blood pressure
Überwiegend Mechanismus / Beobachtung3 Studien
Therapeutic & clinical
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 34 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
100%
über Studien hinweg
Untersuchte Personen
9,737
typische Studie: 53 Personen
Stärkste Designs
34
9 gepoolt, 25 randomisiert
Zeigte Nutzen
92%
12/13 Studien
Wie lange Studien liefen
1–4 Wochen
3
1–3 Monate
2
3+ Monate
2
Untersuchte Populationen
Adults4
Adults with obesity2
Healthy adults2
Type 2 diabetes mellitus patients2
Aktives Forschungsgebiet
17 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024
200520152026
1Body weight reductionMeta-AnalyseCited 11×n=6,171 · very large study2023
We conducted random-effects network meta-analysis with a Frequentist framework to estimate mean difference [MD] and 95% confidence interval [CI] of the effect of nutraceuticals on weight loss.
Shahinfar H et al. · Pharmacological research (2023)
Spürbar Nutzen
← SchlechterKein EffektBesser →
We conducted random-effects network meta-analysis with a Frequentist framework to estimate mean difference [MD] and 95% confidence interval [CI] of the effect of nutraceuticals on weight loss.
Supplementations with green tea (MD: -1.25 kg, 95%CI: -1.68, -0.82) and glucomannan (MD: -1.36 kg, 95%CI: -2.17, -0.54) demonstrated small weight loss, also the certainty of evidence was rated low.
Based on our findings, supplementations with nutraceuticals can result in a small weight loss in adults with overweight or obesity.
2Type II diabetes managementMeta-AnalyseCited 5×n=440 · medium study2023
Our analysis indicates that glucomannan is an effective nutritional intervention for type II diabetes.
Zhang Z et al. · Nutrients (2023)
We searched databases including PubMed, Cochrane, the comprehensive biomedical research database (Embase), Web of Science, and China National Knowledge Infrastructure (CNKI) for literature on glucomannan and type II diabetes.
Six randomized controlled trials (RCTs) were eligible (n = 440 participants) to be included in our analysis.
Our analysis indicates that glucomannan is an effective nutritional intervention for type II diabetes.
Data from 6 trials suggested no impact of KJM on apolipoprotein B.Conclusions: Our findings support the intake of ∼3 g KJM/d for reductions in LDL cholesterol and non-HDL cholesterol of 10% and 7%, respectively.
While some dietary supplements containing isolated organic compounds warrant further investigation to determine efficacy and safety, there is currently insufficient evidence to recommend any of these dietary supplements for weight loss.
Bessell E et al. · International journal of obesity (2005) (2021)
There was no statistically significant effect on weight for fructans compared to placebo (p = 0.24).
While some dietary supplements containing isolated organic compounds warrant further investigation to determine efficacy and safety, there is currently insufficient evidence to recommend any of these dietary supplements for weight loss.
The evidence from available RCTs does not show that glucomannan intake generates statistically significant weight loss.
Onakpoya I et al. · Journal of the American College of Nutrition (2014)
Kein klarer Effekt
← SchlechterKein EffektBesser →
A meta-analysis (random effect model) of 8 RCTs revealed a nonstatistically significant difference in weight loss between glucomannan and placebo (mean difference [MD]: -0.22 kg; 95% confidence interval [CI], -0.62, 0.19; I(2) = 65%).
The evidence from available RCTs does not show that glucomannan intake generates statistically significant weight loss.
Future trials should be more rigorous and better reported.
11Weight management and metabolic indicatorsSystematische Übersicht2026
This review emphasized the need for purpose-driven supplement selection that integrates efficacy, safety, usage context, and evidence level, and the importance of consumers' critical information appraisal capacity, supported by structured information provision and education.
Lee H et al. · Nutrients (2026)
PubMed, MEDLINE, and Google Scholar databases were searched for studies published between 1 January 2020 and 10 October 2025.
Although some studies have reported improvements in weight and metabolic indicators, consistent scientific evidence has not yet been established.
This review emphasized the need for purpose-driven supplement selection that integrates efficacy, safety, usage context, and evidence level, and the importance of consumers' critical information appraisal capacity, supported by structured information provision and education.
13Body weight reductionRCTCited 10×n=112 · medium study2024
Dietary supplementation with glucomannan, inulin, and psyllium effectively promotes weight loss and improves body composition in individuals with obesity, particularly those with specific genetic polymorphisms.
Pokushalov E et al. · Nutrients (2024)
Kaum spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
The experimental group showed significant reductions in body weight (treatment difference: -4.9%; 95% CI: -6.9% to -2.9%; p < 0.01) and BMI (treatment difference: -1.4 kg/m2; 95% CI: -1.7 to -1.2; p < 0.01) compared to placebo.
Further significant decreases in fat mass (treatment difference: -13.0%; 95% CI: -14.4 to -11.7; p < 0.01) and visceral fat rating (treatment difference: -1.3; 95% CI: -1.6 to -1.0; p < 0.01) were noted.
Homozygous minor allele carriers experienced greater decreases in body weight (treatment difference: -3.2%; 95% CI: -4.9% to -1.6%; p < 0.01) and BMI (treatment difference: -1.2 kg/m2; 95% CI: -2.0 to -0.4; p < 0.01) compared to heterozygous allele carriers.
This study suggests that manipulating the human gut microbiome through dietary interventions could be a promising therapeutic approach to managing prediabetes and preventing or delaying diabetes.
Beteri B et al. · Nutrients (2024)
The intervention group showed a significant increase in alpha diversity and butyrate-producing bacteria, with reductions in HbA1c and FPG levels below prediabetes thresholds.
Measurements included gut microbiota composition, glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), plasma lipids, anthropometry, body composition, blood pressure, and dietary intake.
No significant changes were observed in the placebo group.
15Gastrointestinal symptoms in functional constipationRCTCited 1×n=66 · small study2025
Konjac glucomannan significantly ameliorated gastrointestinal symptoms in elite athletes with functional constipation, potentially via modulation of the gut microbiota.
Zhu Y et al. · European journal of nutrition (2025)
Compared to the placebo group, the KGM group exhibited significant improvements in PAC-SYM, PAC-QoL, BMF, and BFI scores (p < 0.05 for all).
Konjac glucomannan significantly ameliorated gastrointestinal symptoms in elite athletes with functional constipation, potentially via modulation of the gut microbiota.
16Glycaemic response and satiationCrossoverCited 1×n=16 · very small study2025
These novel findings suggest that SB can modulate insulin response and influence appetite regulation, highlighting its potential use in weight management strategies.
Ancu O et al. · European journal of nutrition (2025)
SBD intake significantly reduced the insulin concentration compared to dextrose alone at 45, 75, and 90 min post-intake.
These novel findings suggest that SB can modulate insulin response and influence appetite regulation, highlighting its potential use in weight management strategies.
17Metabolic syndrome managementRCTCited 6×n=58 · small study2024
Our study shows that the food supplement tested is a valid and safe alternative therapeutic approach in the management of MetS and all its resulting risk factors, as its efficacy has been demonstrated across anthropometric, glucose, lipid and hepatic parameters.
Citarrella R et al. · Nutrients (2024)
Fifty-eight subjects with MetS and T2DM or impaired glucose tolerance assuming metformin, were randomly assigned to take a food supplement of glucomannan, D-chiro-inositol, Cinnamomum zeylanicum blume and inulin at a daily fixed dose of 4 g orally for four months.
Body weight, waist circumference, plasma lipid profile (total cholesterol, LDL, HDL and triglyc-erides), plasma glycaemic profile and visceral adiposity index (VAI) were measured at baseline and after four months of supplementation.
Our study shows that the food supplement tested is a valid and safe alternative therapeutic approach in the management of MetS and all its resulting risk factors, as its efficacy has been demonstrated across anthropometric, glucose, lipid and hepatic parameters.
18Hunger intensity and waist circumference reductionRCTCited 5×n=42 · small study2023
Forty-two participants aged 18 to 45 years completed our randomized, double-blind, placebo-controlled clinical trial.
Fernandes ACS et al. · International journal of biological macromolecules (2023)
Forty-two participants aged 18 to 45 years completed our randomized, double-blind, placebo-controlled clinical trial.
Participants were randomly assigned to consume for fourteen days, 2 candies per day, containing 250 mg of KGM or identical-looking placebo candy with 250 mg of flaxseed meal, shortly after breakfast and dinner.
Glucomannan supplements administered over 8 weeks were well tolerated but did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters.
Keithley JK et al. · Journal of obesity (2013)
Glucomannan supplements administered over 8 weeks were well tolerated but did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters.